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Abstract 
Mammalian small heat-shock proteins (sHSPs) are molecular chaperones that form polydisperse and 
dynamic complexes with target proteins, serving as a first line of defense in preventing their aggregation 
into either amorphous deposits or amyloid fibrils. Their apparently broad target specificity makes sHSPs 
attractive for investigating ways to tackle disorders of protein aggregation. The two most abundant 
sHSPs in human tissue are αB-crystallin (ABC) and HSP27; here we present high-resolution structures of 
their core domains (cABC, cHSP27), each in complex with a segment of their respective C-terminal 
regions. We find that both truncated proteins dimerize, and although this interface is labile in the case of 
cABC, in cHSP27 the dimer can be cross-linked by an intermonomer disulfide linkage. Using cHSP27 as a 
template, we have designed an equivalently locked cABC to enable us to investigate the functional role 
played by oligomerization, disordered N and C termini, subunit exchange, and variable dimer interfaces in 
ABC. We have assayed the ability of the different forms of ABC to prevent protein aggregation in vitro. 
Remarkably, we find that cABC has chaperone activity comparable to that of the full-length protein, even 
when monomer dissociation is restricted through disulfide linkage. Furthermore, cABC is a potent 
inhibitor of amyloid fibril formation and, by slowing the rate of its aggregation, effectively reduces the 
toxicity of amyloid-β peptide to cells. Overall we present a small chaperone unit together with its atomic 
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Mammalian small heat-shock proteins (sHSPs) are molecular chap-
erones that form polydisperse and dynamic complexes with target
proteins, serving as a first line of defence in preventing their
aggregation into either amorphous deposits or amyloid fibrils.
Their apparently broad target specificity makes sHSPs attractive
for investigating how to tackle disorders of protein aggregation.
The two most abundant sHSPs in human tissue are αB-crystallin
(ABC) and HSP27; here we present high-resolution structures of
their core domains (cABC, cHSP27), each in complex with a segment
of their respective C-terminal regions. We find that both truncated
proteins dimerise, and while this interface is labile in the case
of cABC, in cHSP27 the dimer can be cross-linked by an inter-
monomer disulphide linkage. Using cHSP27 as a template we have
designed an equivalently locked cABC to enable us to investigate
the functional role played by oligomerisation, disordered N- and
C- termini, subunit exchange and variable dimer interfaces in ABC.
We have assayed the ability of the different forms of ABC to
prevent protein aggregation in vitro, and remarkably find that
cABC has chaperone activity comparable to the full-length protein,
even when monomer dissociation is restricted through disulphide
linkage. Furthermore, cABC is a potent inhibitor of amyloid fibril
formation, and, by slowing the rate of its aggregation, effectively
reduces the toxicity of amyloid-β peptide to cells. Overall we
present a small chaperone unit together with its atomic coordi-
nates that potentially enable the rational design of more effective
chaperones and amyloid inhibitors.
αB-crystallin | small heat-shock protein | molecular chaperone | amy-
loid | X-ray crystallography
Introduction
The proteome is inherently metastable (1, 2), and therefore
the cell is required to actively maintain protein homeostasis (or
“proteostasis”) through the balancing of a multitude of biochem-
ical pathways (3). The breakdown of this steady state can lead
to a variety of diseases, many of which are characterised by the
aggregation and deposition of misfolded proteins (4). Molecular
chaperones, proteins that act to prevent improper polypeptide
associations, are crucial components of the cellular proteostasis
machinery (5, 6). They include the small heat-shock proteins
(sHSPs), which are found in organisms across all branches of the
tree of life and play an important role in preventing protein mis-
folding and aggregation (7, 8). In general the sHSPs are capable of
intercepting destabilized targets (9), and either: holding them in a
refolding competent state; preventing them from aggregating into
unrecoverable deposits; or directing them towards degradation
(10). αB-crystallin (ABC) is an abundant mammalian sHSP, the
expression of which is constitutive in most human tissues and
upregulated in a variety of pathological disorders (11). The chap-
erone activity of ABC has been established for over two decades
(12), and it is associated with amyloid fibril deposits in vivo
that are characteristic of protein misfolding diseases including
Alzheimer’s and Parkinson’s diseases (13-15).
Proteins enter the amyloid cascade from their native state
and form insoluble fibrils via various intermediates, including
oligomeric forms (16, 17). Both amyloid fibrils and oligomers
are harmful to cells, however the latter appear to be more toxic
(18). ABC has been shown to mitigate amyloid toxicity to cells in
culture (19), to interact directly with amyloid oligomers in vitro
(20), and to prevent the fibrillation of a variety of targets (21-25).
Additionally ABC has been shown to bind to mature amyloid-β
peptide (Aβ1-42) (22, 24), α-synuclein (23, 25), and apolipoprotein
C-II (apoC-II) fibrils (26), apparently coating them and pre-
venting their elongation (21). An understanding of how ABC
carries out these activities has been hindered by the structural and
dynamical complexities of this chaperone. ABC, as is typical for
most metazoan sHSPs, consists of a dimeric building block that
assembles via terminal interactions into a polydisperse ensemble
(8). In ABC, these oligomers range from approximately 10 to 50
subunits and readily interconvert via the exchange of monomers
(27), in a process that facilitates the formation of heterooligomers
between different sHSPs (28). While several new models have
recently been developed for ABC oligomers, a consensus as to
their quaternary structure remains to be reached (8, 29).
The sequence of ABC can be divided into an
immunoglobulin-like “α-crystallin domain” (ACD) that mediates
Significance
We find that the core domain of the human molecular chaper-
one αB-crystallin can function effectively in preventing protein
aggregation and amyloid toxicity. The core domain represents
only half the total sequence of the protein, yet it is one of the
most potent known inhibitors of the aggregation of amyloid-
β, a process implicated in Alzheimer’s disease. We have de-
termined high-resolution structures of this core domain, and
investigated its biophysical properties in solution. Our findings
reveal that the excised domain efficiently prevents amyloid
aggregation and thereby reduces the toxicity of the resulting
aggregates to cells. The structures we present of these do-
mains should represent useful scaffolds for the design of novel
amyloid inhibitors.
Fig. 1. Crystal structures of cABC and cHSP27. (A) cABC crystallizes as a dimer
of dimers, with one C-terminal peptide of sequence ERTIPITRE (red) bound to
each monomer. (B) Two immunoglobulin-like cABCmonomers assemble into
a dimer through pairwise and anti-parallel interactions between extended
β6+7 strands. In this structure the dimer is found in the APIII register. The
palindromic C-terminal peptide binds to a hydrophobic groove between β4
and β8 strands, in an anti-parallel direction to the β8 strand (inset, direction
N to C illustrated by yellow arrow). (C) The crystal structure of cHSP27
reveals a dimer similar to cABC, rich in β sheet structure and with C-terminal
peptides bound. cHSP27 however is in the APII register, with C137 (thiol
coloured in yellow) located about a two-fold axis at the dimer interface
(inset). C137 is reduced in the structure due to the presence of reductant
during crystallisation, but can readily be oxidised (Fig. 4).
dimerization, and is flanked by N- and C-terminal regions that
are poorly conserved and variable in length between sHSPs (7,
8). Various regions of the ABC sequence have been implicated
as potential binding sites, but there is little consensus (30-34).
Moreover, it even remains unclear whether the polydisperse
oligomeric ensemble of ABC, the oligomeric dissociation that
mediates subunit exchange, or remodelling of the dimer interface
is responsible for chaperone function (8). Models have been
proposed wherein sub-oligomeric forms, which are in equilibrium
with the assembled state, are the active chaperoning unit. This
idea is based on the observation that solution conditions that
accelerate subunit exchange also lead to increased chaperone
activity (35). Conversely, other studies have demonstrated that
ABC can still function as a chaperone despite being cross-linked
as an oligomer (36), and that mutations that slow its subunit
exchange kinetics do not necessarily diminish its activity as a
chaperone in vitro (37).
These apparent conflicts likely stem from the intrinsic het-
erogeneity of ABC and the difficulty in assessing the interplay
Fig. 2. Structural differences between cHSP27 and cABC. (A) Sequence
alignment of the two domains coloured to highlight differences in amino-
acid composition (strongly dissimilar, red; dissimilar, orange; weakly dissim-
ilar, yellow, see methods). The two domains are clearly highly similar (54.7
% identity), though differences are distributed throughout the sequence.
(B) Mapping the disparate residues on the cABC (left) and cHSP27 (right)
structures (colouring as in A) reveals them to be spread over the entire
structure. (C)An expansion of the boxed region in B reveals a charge network
formed by residues E99, H101, E117, and H119 in cABC (left) that is absent in
cHSP27 (right) where the equivalent residues are E119, T139, T121 and C137.
between its structural and dynamical aspects (8, 29). Here we
have gained insight into the chaperone activity of ABC, and the
prevention of protein aggregation in general, by establishing a
minimal, yet chaperone-active, unit of ABC that is suitable for
structural studies. We drew inspiration from recent structures
of the ACD that have revealed the ABC dimer interface to be
composed of paired “β6+7” strands (38-41). Interestingly, their
anti-parallel interaction has been crystallized in two different
registers, termed API and APII (41), with a third (APIII) having
been found for the related HSP20 (38). The three registrations
have different amounts of buried surface area in the dimer
interface, resulting from monomers being progressively shifted
outward relative to one another in APII and APIII relative to API.
We have engineered a construct comprising exclusively the core
domain of ABC (cABC), which allowed us to test the relationship
between oligomeric state, subunit exchange, registration state,
and chaperone function of ABC.
Our experimental strategy combines X-ray crystallography
with native mass spectrometry (MS) and nuclear magnetic res-
onance spectroscopy (NMR) to examine the structure of cABC.






































































Fig. 3. NMR and IM reveal APII as the dominant registration state for cABC in
solution. (A) Crystal structure of cABCE117C in which the introduced cysteine
acts to lock the domain into a dimer in the APII register. The disulphide
bond formed between two monomers is shown in the inset. The overall
structure of this engineered ACD is closely similar to that of cABC. (B) The
three registers of the ABC dimer observed by X-ray crystallography: API (PDB
ID: 3L1G), APII (2WJ7), and APIII (present work, 4M5S). Red lines indicate the
vector between α-carbons of residues E117 on the two monomers, which
is located on a two-fold axis in APII. The distance between two modelled
cysteines at position 117 is close enough for disulphide bond formation only
in APII (9.13 Å between the two thiols in API, 0.93 Å in APII, and 6.5 Å in APIII).
(C) 1H-15N-HSQC spectra of cABC (blue) cABCE117C (orange) acquired under
identical and oxidizing solution conditions. Overlap of peaks is represented
by purple. Peaks with significant shifts in themutant are labelled on the plot.
Dotted lines indicate peak movement in the mutant compared to cABC, and
asterisks unassigned peaks. The spectra overlay very well, indicating that the
fold of the two proteins is very similar. (D) A heat map of CSP projected
onto the structure of cABC (largest CSP, red; lowest, white) reveals that the
most significant changes in chemical shift are observed near C117. (E) IM
measurements of the cABC (blue) and cABCE117C (orange) 7+ charge state
(see Fig. 4E,F) under oxidizing conditions reveal very similar CCS distributions.
Dashed lines indicate anticipated CCS values of API, APII, and APIII. As the
CCS distribution of cABC matches that of cABCE117C, which is fixed as an APII
dimer, we can infer that cABC preferentially populates the APII register.
cABC can populate three different registers, and that the APII
form is predominantly populated in solution. Through compar-
ison with a new structure of the HSP27 core domain (which
Fig. 4. Quaternarydynamics of cABC and cABCE117C. (A) Nanoelectrospray
MS of cABC reveals two charge state distributions corresponding to an
equilibrium of monomers (triangles) and dimers (squares). (B) A titration
series of cABC reveals an increase in the abundance of dimer (dark blue)
relative to monomer (light blue) as the concentration is increased (2, 4, 8,
16 and 32 μM, front to back). Spectra are normalized such that the most
intense peak in each spectrum is equal to 100%. The shaded area indicates
the 7+ charge state of the dimer. (C) Amass spectrum of cABCE117C, obtained
under the same conditions as for cABC in A, reveals the exclusive presence of
dimers due to disulphide bond formation. (D) In the presence of reductant
cABCE117C reverts to a concentration-dependent equilibrium of monomers
(orange) and dimers (brown) (concentrations as in B) (E) A mass spectrum of
unlabelled cABC mixed with 13C-labelled cABC, acquired as soon as possible,
and focussing solely on the 7+ charge state (shaded in C). Both homo-
and heterodimers are observed, indicating rapid subunit exchange. (F) An
equivalent experiment to that in E carried out with cABCE117C under reducing
conditions demonstrates fast subunit exchange as observed for cABC.
we also present here), we have engineered a cysteine mutant of
cABC (cABCE117C) that can be locked into a dimeric state in the
APII registration. This protein is therefore unable to exchange
monomers under oxidizing conditions. We show that both cABC
and cABCE117C can strongly inhibit amorphous aggregation, amy-
loidogenesis and amyloid toxicity, all as effectively as the wild-
type protein. Together our data demonstrate that the core domain
of ABC is responsible for its potent molecular chaperone func-
tion, which is retained regardless of stoichiometry or registration
state of the dimer.
Results
An alternative strategy to crystallise mammalian sHSPs
In a novel approach to crystallise mammalian ACDs, we
designed a system composed of a core unit of ABC (residues
68-153, cABC), and a peptide mimicking its C-terminal region
(residues 156-164, ERTIPITRE), to avoid the runaway domain
swapping that resulted in a polymer-like crystal array in our
previous study (41). Co-crystallisation of cABC and the peptide
produced crystals that led to structure determination at 1.35
Å (Table S1). The structure of cABC reveals a crystal packing
of tetrameric units, assembled essentially as a dimer of dimers
(Fig. 1A). One peptide is bound to each cABC monomer in an
orientation anti-parallel to the β8 strand (Fig. 1B), the inverse of
that in our previous structure of ABC (41). This bi-directionality
is enabled by the palindromic nature of the peptide (42), and is
consistent with the binding observed in NMR experiments (43).
The two monomers form a dimer interface in which they are
slightly bent relative to each other (Fig. 1A), reminiscent of a
structure of ABC obtained by means of solid-state NMR (40)
(Fig. S1). The angle between monomers is however larger in our






































































Fig. 5. Fig. 5: In vitro chaperone activity of ACDs.
(A) Dose-dependent inhibition of reduction-induced
α-lac aggregation by cABC. Molar ratios are indicated
as cABC:α-lac. Even at sub-stoichiometric quantities of
cABC, significant chaperone activity is observed. (B)
Comparing different constructs of ABC at a molar ra-
tio of 1:5 (chaperone:α-lac) reveals cABC to be equiv-
alently potent to the full-length protein. cABCE117C
is slightly more effective than cABC, likely due to
altered surface properties around the introduced cys-
teine (Fig. S3). (C) Assaying κ-casein fibrillation under
reducing (upper) and oxidising (lower) conditions in
the presence of our ABC constructs at a molar ratio of
1:2 (chaperone: κ-casein) demonstrates that they are
capable of slowing aggregation. cABC is less efficient
than the full-length protein in both conditions, while
cABCE117C is more effective than cABC, mirroring the
data in B. (D) The ABC constructs are also potent
inhibitors of Aβ1-42 fibrillation at a molar ratio of 1:20
(chaperone:Aβ1-42). Under reducing conditions (up-
per), all three constructs perform equivalently, while
under oxidising conditions (lower), cABCE117C is more
effective than cABC. This suggests that locking into an
APII dimer improves chaperone action in this assay. In
all cases (A-D), a representative aggregation assay is
shown as well as the percentage protection. Error bars
correspond to mean ± standard error of the mean,
with n=3. * p<0.05, ** p<0.01. (E) Cell viability assays
upon addition of Aβ1-42 to HEK293, HeLa, and PC12
cells. Aβ1-42 on its own (red) causes a decrease in
viability to 40 %, while cABC (dark blue), cABCE117C
(brown), or buffer (grey) have no effect. Aβ1-42 in-
cubated in the presence of increasing amounts of
cABC (blue) and cABCE117C (orange) is less toxic than
in the absence of chaperone. Molar ratios indicated
are chaperone:Aβ1-42, with an Aβ1-42 concentrationof
0.5 μM in all experiments (except the controls without
Aβ1-42). In all cases a clear concentration dependence
to chaperone protection is observed. Error bars cor-
respond to mean ± standard error of the mean, with
n=4. * p<0.05.
intrinsic twist of the monomers (Fig. S1A). Notably, we find that
the dimer is in the APIII register, a state previously only observed
in the structure of HSP20 (38). A comparison of the registers
for ABC reveals the APIII structure to have 685.1 Å2 of buried
surface area, compared to 694.1 in APII (PDB ID: 2WJ7) and
820.7 Å2 in API (3LIG). Together with structures of truncated
ABC constructs in the API (41) and APII states (38-40), this
reveals that ABC can populate multiple dimer interface registers
that differ in their exposed surface area.
The core domain dimer of HSP27 has cysteines located about a
two-fold axis
In order to interrogate the potential role of these different
registers we drew inspiration from HSP27, a related human sHSP
that has a cysteine residue (C137), located within the β6+7
strand, that can readily be oxidised (44). By employing our co-
crystallisation strategy we succeeded in determining the structure
for the HSP27 ACD (residues 86-169, cHSP27) in complex with
its C-terminal peptide (residues 179-185, ITIPVTF) (Table S1).
We find that cHSP27 forms a canonical dimer, in an APII reg-
ister, and with the C-terminal peptide bound in an anti-parallel
orientation relative to the β8 strand (Fig. 1C). Our structure
superimposes well with a previous one in which monomers as-
sembled into a non-canonical hexamer within the crystal lattice
(backbone RMSD = 0.45 Å2 comparing monomers, Fig. S1B),
and the registration state is consistent with small-angle X-ray
scattering data (45). The structures are slightly different around
the loop between β5 and β6+7 strands, which contained several
point mutations in the previous structure and was disordered. We
find this region to be ordered in an extended conformation along
the β6+7 sheet of the dimer interface. This can be explained by






































































the formation of a β2 strand consistent with structures obtained
for other metazoan ACDs (Fig. S1C).
Differences in the primary sequences of cABC and cHSP27
are distributed over the entire domain, with slightly more dis-
parity observed in flexible loops between successive β-strands
(Fig. 2A). While the monomeric fold is nearly identical in the
two proteins (Fig. 2B), in cHSP27 the β-sandwich is splayed
outward by ≈2.5 Å. This can be attributed to the combined effect
of several substitutions (Fig. S1E). The most striking difference,
however, is found for residues located next to C137 on the β6+7
strand in HSP27. In cABC there is a charge network of two
histidines (H101 and H119) and two glutamates (E99 and E117)
that implies pH sensitivity (Fig. 2C) (39, 40). In cHSP27, these
histidines are replaced by threonines and E117 by C137, resulting
in a disruption of the charge network (Fig. 2C). Moreover, our
structure reveals that C137 is located on a central two-fold axis
about the dimer interface, and is in a conformation compatible
with disulphide bond formation. These differences are consistent
with the observation that the ABC dimer interface is pH sensitive
(27, 40), and HSP27 activity shows redox dependence (46).
An APII ‘locked’ cABC dimer
Motivated by the cHSP27 structure we engineered a cysteine
into cABC at position E117, which aligns to C137 in HSP27
(Fig. 2A), and is located about the two-fold axis in the APII
register (Fig. 1C). We crystallized this cABCE117C construct using
our co-crystallisation method (Table S1), revealing a fold very
similar to cABC and comparable curvature of the dimer interface
(Fig. 3A). However, in one of the two dimers comprising the
asymmetric unit, this dimer was covalently locked by a disulphide
bond between monomers rendering it unable to access registers
other than APII (Fig. 3B). In the locked dimer, the loops between
the β5 and β6+7 strands are disordered in the crystal lattice, but
are ordered in the other dimer (Chains E and G) (Fig. S2A).
There is near-perfect agreement in side-chain positions between
cABC and cABCE117C (backbone and side-chain RMSD = 0.33
Å2). The two structures only differ significantly in that the β5
and β6+7 strands are elongated in the APIII register of cABC.
The disulphide bond in the cABCE117C structure does not lead
to unusual torsion angles in the β-sheet around the bond, nor
in the dihedral angles associated with the bond (Fig S2B). While
the introduction of strain into anti-parallel β–sheets by disulphide
bonds between register-paired cysteines has been proposed as
a mechanism of redox regulation (47), our cABCE117C structure
hints that redox regulation in HSP27 is achieved via another
mechanism.
cABC predominantly populates the APII register
To assess whether cABCE117C adopts the same monomeric
fold as cABC in solution we recorded 1H-15NHSQC NMR spectra
for both cABC and cABCE117C under oxidising conditions. In both
cases, well-dispersed resonances were observed indicative of a
folded structure and consistent with data for similar constructs
(43, 48). For most cross-peaks in the cABC spectrum, there is
a corresponding cross-peak for oxidized cABCE117C (Fig 3C).
Additional cross-peaks are visible in the cABCE117C spectrum
that likely result from differences in subunit exchange dynamics
between cABC and cABCE117C (48). To assess the magnitude of
any changes we determined the change in cross-peak position
in both the 1H and 15N dimension (chemical-shift perturbation,
CSP) between cABC and cABCE117C based on a previous assign-
ment (48) (Fig, 3D). In most cases the CSPs are <0.16 ppm,
which is considerably smaller that those observed in experiments
probing the binding of ligands to ABC (43). The two largest CSPs
(≈0.7 ppm) are E117 (the site of mutation) and H119, which is
hydrogen-bonded to E117 in our cABC structure. Mapping these
small CSPs onto the structure of cABC reveals them to cluster
around the site of mutation (Fig. 3D), as expected due to the
change in chemical environment caused by the substitution of
side-chains. The monomeric folds of cABC and cABCE117C in
solution are therefore extremely similar, despite cABCE117C being
locked into the APII registration.
To investigate which register cABC populates at equilibrium,
we employed ion mobility spectrometry (IM), a technique that
reports on the overall size of the molecule in terms of a rota-
tionally averaged collisional cross section (CCS) (49). Theoretical
calculations based on the crystal structures of the different forms
(Fig. 3B) predict API and APIII to differ from APII in CCS by -4.5
% and 15.8 %, respectively (Fig. 3E, dashed lines). Comparison
of IM data for cABC and cABCE117C under oxidizing conditions
however reveals no noticeable differences in CCS distributions
(Fig 3E), even though the disulphide-locked cABCE117C is unable
to access either API or APIII. This, combined with the similarity of
monomeric folds of cABC and cABCE117C, indicates that, outside
of a crystal lattice, cABC exists predominantly in the APII register.
The dynamics of cABCE117C under reducing conditions are equiv-
alent to cABC
In order to interrogate the dynamics of cABC we performed
nanoelectrospray MS measurements under conditions that pre-
serve non-covalent interactions in vacuum (50). A mass spec-
trum obtained for cABC features two charge-state distributions,
centred on 2000 m/z and 2500 m/z, which partially overlap and
correspond to monomers and dimers, respectively (Fig 4A). At
this concentration (8 μM, based on the molar mass of a monomer)
a substantial amount of monomer is observed. Increasing the con-
centration of cABC to 32 μM results in an increasing abundance
of dimers (Fig. 4B), consistent with a KD on the order of a few μM
(51). cABCE117C under oxidizing conditions only forms dimers,
in line with the disulphide bond formation between monomers
observed in the crystal structure (Fig. 4D). Upon the addition of
reductant, cABCE117C immediately reverts to a monomer-dimer
equilibrium with a KD comparable to that of cABC (Fig. 4E).
To characterize the kinetics of the monomer-dimer equilib-
rium in cABC, we performed experiments wherein mass spectra
of cABC and a 13C-labelled equivalent were acquired as soon as
possible after mixing at 4 °C. Examination of the region of the
spectrum corresponding to dimers reveals 12C12C- and 13C13C-
homodimers, and 12C13C-heterodimers of cABC. Notably, these
three dimeric forms are observed at a 1:1:2 ratio (Fig. 4E), as
would be expected statistically upon complete equilibration of
this equimolar mixure. As such, complete exchange is reached
on a timescale faster than the dead-time of the experiment.
This corresponds to a lower limit for the off-rate constant of a
monomer from the dimer of 0.1 s-1 , approximately five orders of
magnitude faster than a monomer dissociating from an oligomer
of ABC at the same temperature (27). The equivalent experiment
performed for cABCE117C under oxidising conditions shows no
subunit exchange, even after prolonged incubation, as anticipated
due to the covalent linkage between homodimers. In the pres-
ence of reductant, cABCE117C exchanges subunits as rapidly as
cABC (Fig. 4D,F). Combined, these results demonstrate that
cABCE117C is a redox-sensitive protein that exists as a stable cross-
linked dimer under oxidising conditions, and immediately reverts
to a monomer-dimer equilibrium with extremely fast subunit
exchange dynamics, comparable to those of cABC, upon the
addition of reductant.
cABC can prevent amorphous protein aggregation in vitro
The cABC system represent an excellent means to probe
the chaperone activity of the core domain itself, and to study
the importance of the monomer-dimer equilibrium and its as-
sociated subunit-exchange dynamics. In order to investigate this,
we assayed the ability of cABC, cABCE117C and full-length ABC
to protect three very different targets: α-lactalbumin (α-lac); κ-
casein; and the amyloid β-peptide (Aβ1-42). These polypeptides
differ in their amino-acid sequence, molar mass, mechanism and






































































We optimised the chaperone:target molar ratios such that our
assays exhibited measurable aggregation of the targets, in order
to be sensitive to small differences in chaperone activity.
We first monitored the ability of the different constructs
to inhibit the reduction-induced amorphous aggregation of α-
lac at 37 °C. In the absence of chaperone, after a lag phase
of about 20 minutes, we observed a rapid increase in apparent
absorbance due to light scattering (Fig. 5A, red), indicating the
aggregation of α-lac (52). Upon addition of cABC, we found a
considerable delay to the onset and reduction in the rate of α-lac
aggregation (Fig 5A, blue). The extent of protection conferred
was strongly dependent on the amount of chaperone, though
significant protection (p<0.01) was observed even at molar ratios
as low as 1:80 (cABC:α-lac). This indicates that cABC affords
potent protection against amorphous protein aggregation, at sub-
stoichiometric amounts, and in a dose-dependent manner.
In order to quantify the relative efficacy of protection relative
to full-length ABC and cABCE117C, we performed a comparative
assay at a ratio of 1:5 (chaperone:α-lac). All three chaperones
significantly delayed and slowed α-lac aggregation (Fig. 5B).
Remarkably, comparison of cABC and full-length ABC reveals
no significant difference in their activity. Notably cHSP27, despite
being of similar fold to cABC, displayed minimal chaperone
activity in this and other assays (Fig. S3). As such it can be
regarded as a negative control, and demonstrates the specificity
of the chaperone action observed for the constructs of ABC.
In this assay, we find therefore that the ACD in ABC is
entirely sufficient for chaperone function (Fig. 5B). Notably,
we observe that cABCE117C is more effective at preventing ag-
gregation of α-lac than cABC. It is important to consider that
the presence of DTT in this assay means that the disulphide
bond in cABCE117C is reduced (Fig. 4F), so this increased activity
cannot be ascribed to the exclusive presence of an APII-locked
dimer. Instead we observe that cABCE117C displays increased
binding, relative to cABC, of the hydrophobic probe bis-ANS
(4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid), revealing an
increased solvent-accessible hydrophobic surface area (Fig. S4).
The slight differences in structure between cABC and cABCE117C
revealed by our NMR experiments (Fig. 3D) provide one possible
rationale for the difference in chaperone activity.
cABC can prevent amyloid fibril formation in vitro
We next tested the ability of cABC to prevent amyloid fibril
formation using two model systems: κ-casein and Aβ1-42. In these
experiments, fibril formation is assayed by monitoring the char-
acteristic red-shift in fluorescence of the dye thioflavin T (ThT)
upon binding to amyloid structures. In the absence of chaperone,
κ-casein forms fibrils relatively slowly (over a period of >20
hours), without a significant lag phase (Fig. 5C). The timescale of
this aggregation is not significantly altered with the presence (up-
per panel) or absence (lower panel) of the reductant DTT. At a
molar ratio of 1:2 (chaperone: κ-casein), ABC slows κ-casein fibril
formation under both oxidising and reducing conditions (Fig. 5C).
At an equivalent ratio, cABC also retards amyloidogenesis, and
only slightly less effectively than the full-length protein. Notably,
cABCE117C is more effective at slowing κ-casein aggregation than
cABC. This improved activity is observed under both oxidising
and reducing conditions, in other words independent of whether
the chaperone is locked into APII dimers. This suggests that the
difference in activity in this case is due to the altered surface
properties of cABCE117C compared to cABC (Fig. 3D, Fig S4),
as observed in our α-lac assay (Fig. 5B).
In order to test our constructs in preventing the aggregation
of a target that forms fibrils more rapidly, we assayed their ability
to inhibit Aβ1-42 amyloidogenesis. In the absence of chaperone,
this peptide aggregates over a period of approximately 3 hours,
both in the presence and absence of DTT (Fig. 5D). At a molar ra-
tio 1:20 (chaperone:Aβ1-42), and in both conditions, we found that
all three constructs dramatically slowed aggregation. Notably,
no significant difference was observed for cABC relative to the
full-length protein (Fig. 5D). Under reducing conditions (upper
panel), cABC and cABCE117C have equivalent chaperone ability
in this assay. However, under oxidising conditions (lower panel),
cABCE117C is more effective at inhibiting Aβ1-42 fibril formation
than cABC. Therefore, locking cABC into an APII dimer makes
it a more potent chaperone in this assay.
The interaction of cABC with aggregating Aβ1-42 reduces toxicity
to cells
To test whether the inhibitory effect of cABC on
Aβ1-42 amyloid formation would result in a decrease in toxicity
we performed assays on cultured cells. Specifically we monitored
the viability of HEK293, HeLa, and PC12 cells upon the addition
of pre-incubated Aβ1-42 (Fig. 5E). In all three cell lines, the
addition of Aβ1-42 resulted in a decrease in viability to about
40%, indicating toxicity of the aggregating peptide. Addition of
solutions of Aβ1-42 that had been incubated in the presence of
chaperone showed a reduction in this toxicity. Notably, not all
cell lines responded equivalently, with both cABC and cABCE117C
being more effective at rescuing HEK293 and HeLa cells than
PC12 cells. While the reasons for this are not known, it is clear
that the protective effect was more pronounced with increasing
ratios of chaperone:Aβ1-42, demonstrating a dose-dependency in
all cases. This mirrors data obtained for full-length ABC (19, 20),
and reveals that the ACD is sufficient to slow the rate of Aβ1-42
aggregation and thereby reduce the toxicity of the aggregating
mixture. Interestingly, in these assays that are performed in
the absence of reductant, we detect a clear increase in potency
for cABCE117C relative to cABC in HeLa cells, and in PC12
only cABCE117C displayed statistically significant potency. This
implies that locking cABC into an APII dimer, which improves
its efficacy in slowing the rate of Aβ1-42 in vitro (Fig. 5D, lower),
results in an associated reduction in toxicity of the aggregating
mixture.
Discussion
Here we have found that the core domain of ABC is a potent in-
hibitor of both amorphous and fibrillar aggregation, and amyloid-
associated toxicity. Previous reports describing alternatively trun-
cated forms of ABC have shown limited chaperone activity to-
wards other target proteins (41, 53). However, our construct
performed comparably to full-length ABC with regards to pro-
tecting α-lac and κ-casein from aggregation at sub-stoichiometric
levels. Remarkably, our amyloidogenesis and cell toxicity assays
of Aβ1-42 places cABC among the most potent known inhibitors
of Aβ1-42 on a molar basis (54). The finding that the ACD can
prevent amyloid formation and toxicity is surprising, and raises
questions about the role of its flanking and relatively unstructured
N- and C- terminal regions, and necessity of the oligomeric form
of ABC.
It is important to recognise that our assays report primarily
on the ability of the ACD to delay aggregation, and not on the
stability of any complexes formed, nor their interactions with the
cellular disaggregation, refolding, or degradation machinery (10,
55). Similarly, we are probing only the chaperone function of
ABC against selected targets, when it is known that the chaperone
has other important roles, including as a major structural compo-
nent of the eye lens, which may require oligomerisation (56). It is
interesting to note that chaperone activity of dimeric sHSPs has
been reported from various organisms, including HSP17.7 from
Deinococcus radiodurans (57), HSP18.5 from Arabidopsis thaliana
(58), and human HSP20 (59). Although these chaperones do
not assemble into oligomers, they still have intact N- and C-
termini. Our results clearly demonstrate that the ACD itself can
be sufficient for chaperone activity, and is not simply a passive






































































We have shown that, against all target proteins tested,
cABCE117C locked into an APII dimer was at least as active
as cABC. This demonstrates that dissociation into monomers,
subunit exchange dynamics, or accessing other dimer registration
states (API or APIII) is not a pre-requisite for the chaperone func-
tion of ABC. This observation is consistent with measurements
made on an equivalent E117C mutation in full-length ABC, which
had activity comparable to the wild-type in preventing rhodanese
from aggregating (44). Furthermore, in all our experiments the
concentration of chaperone used was close to the KD of the
cABC dimer interface, meaning that a sizeable proportion of
the chaperone was monomeric (51). In the case of α-lac and
Aβ1-42 this did not impair chaperone activity, suggesting that the
monomeric ACD is itself chaperone-active. This is consistent with
the observation of monomers being the exchanging unit in ABC
(27). Taken together with the observation that full-length ABC
is active, including when cross-linked to prevent its dissociation
(36), a picture emerges wherein the ACD is chaperone-active, and
its binding surfaces accessible, irrespective of its quaternary state.
Hydrophobic interactions are often hypothesized as the likely
mode of chaperone-target interactions (5, 6). Interestingly, cABC
has few exposed hydrophobic patches, and has fewer than the
structurally similar, yet inactive cHSP27 (Fig. S4). Although we
did measure an increase in exposed hydrophobic surface area in
cABCE117C relative to cABC (Fig. S4), we did not detect major
structural distortions in the monomeric fold due to the muta-
tion in either our NMR or X-ray crystallography experiments.
It is possible therefore, that the increased chaperone activity of
cABCE117C may be due to residue 117 being proximal to the bind-
ing site of cABC, and mutation to cysteine resulting in favourable
changes to the protein surface. Alternatively, we have established
previously that the dimer interface and the β4-β8 groove that
accommodates the C-terminal peptide are allosterically coupled:
strengthening of one results in the weakening of the other (27,
51). As such, it may be that stabilising the dimer interface through
the covalent linkage may increase the accessibility of the groove
as a potential site for target binding.
While cABC is an effective chaperone against the aggregation
of all the targets assayed here, there nonetheless remain differ-
ences in effectiveness of protection compared to full-length ABC.
In the case of α-lac, the core is entirely sufficient for chaperone
function, whereas with κ-casein it is somewhat less active than
full-length ABC. The effect of the E117C mutation resulted in
an increase in potency against α-lac and κ-casein regardless of
its redox state, which could be rationalised by slight differences
in surface hydrophobicity (Fig. S4). Interestingly, cABCE117 was
also more potent against Aβ1-42 aggregation than cABC, but
only when the disulphide bond locked cABCE117 into a dimeric
form. Combined, this suggests there are subtle differences in the
way the ACD interacts with different targets, perhaps through
separate parts of its molecular surface. This is consistent with
observations of different modes of action for amorphous and
amyloidogenic aggregation (60, 61), and chaperone activity for
peptides from different regions of ABC (31, 32).
It is important to note that sequence differences between
cABC and the chaperone inactive cHSP27 are distributed all over
the surface, and do not cluster around either the dimer interface
or the β4-β8 groove (Fig. 2). The small number of differences
in primary amino acid sequence therefore does not point to any
particular patch of the domain that renders cABC active and
cHSP27 inactive. Irrespective of the exact location of the binding
site on cABC, the similarity of the cABC and cHSP27 structures
suggests that specific residues mediate the interaction between
cABC and the targets assayed here. Importantly, the system and
approaches we have developed will enable us to probe structurally
this important function of sHSP. Understanding how such a small
folded protein inhibits amyloid toxicity will potentially be of
great use in the search for effective biotherapeutic strategies for
diseases associated with amyloid fibril formation.
Materials and methods
ABC, cABC and cHSP27 protein expression and purification
Human ABC, cABC (residues 68-153) and cHSP27 (residues 84-176) were
cloned, expressed and purified as described previously (41, 51), with the
exception that in the His-tag buffers phosphate was replaced by TRIS. Trun-
cated proteins were expressed with N-terminal TEV protease cleavable His-
tags and purified by using nickel-affinity chromatography. The N-terminal
His-tag was removed with TEV protease and the protein buffer exchanged
using either a Superdex 75 gel filtration column (GE Healthcare) or two 5 mL
HiTrap desalting columns (GE Healthcare) connected in series. For subunit
exchange experiments, cABC was expressed in M9minimal media containing
13C-labelled D-glucose as the only carbon source and purified as described
above. For NMR experiments, cABC and cABCE117C were expressed in M9
minimal media containing 15N ammonium chloride as the only nitrogen
source.
ABC and HSP27 C-terminal peptide expression and purification
The C-terminal peptides (ABC residues 156-164, ERTIPITRE; HSP27
residues 179-185, ITIPVTF) were either purchased (Biomatik or Genscript), or
expressed recombinantly and purified as described previously (62). Briefly, an
expression construct containing an N-terminal His-tagged maltose binding
protein followed by a TEV protease cleavage site in pET15b (Novagen) was
amplified by PCR using a T7 forward primer and reverse primer with a 5’
overhang containing the DNA sequence for the C-terminal peptide followed
by a stop codon and XhoI restriction site. The subsequent PCR product was
digested with NdeI and XhoI (New England Biolabs) followed by ligation
using a Quick Ligation kit (New England Biolabs) into pET28b. The fusion
construct was expressed and purified using nickel-affinity chromatography
followed by TEV protease cleavage, leaving an additional N-terminal glycine,
and purification using reverse-phase high performance liquid chromatogra-
phy. Peptide fractions were verified by means of MS, and stored in desiccant
jars at -20 □°C.
Crystallization of cABC and cHSP27 in complex with their C-terminal
peptides
Crystals were grown in hanging-drop plates (VDX, Hampton Research) at
room temperature. A final mixture containing 8-10 mg/mL monomer supple-
mented with 2-3 fold molar excess of the appropriate C-terminal peptide (10
mM stock, in water) was prepared in X-tal buffer (100 mM sodium chloride,
20 mM TRIS, pH 8.0). Crystals of cABC with recombinant C-terminal peptide
grew in 0.1 M SPG (succinic acid, dihydrogen phosphate, glycine) buffer
pH 6.0 and 25 % PEG 1500. Crystals of cABCE117C with synthetic C-terminal
peptide grew in 0.085 M MES pH 6.5, 0.17 M ammonium sulphate, 25.5
% PEG 5000 MME, and 15 % glycerol. A final mixture containing 9 mg/mL
cHSP27 supplemented with 2-fold molar excess of the synthetic C-terminal
peptide (10mM stock, in water) prepared in Xtal buffer supplemented with
1mM DTT was crystallized in Crystal Screen (Hampton Research) condition #6
(0.2 M magnesium chloride, 0.1M TRIS pH 8.5, and 30 % PEG 4,000). With
the exception of cABCE117C, crystals were cryo-protected in mother-liquid
solution containing 20 % glycerol. All crystals were flash-frozen in liquid
nitrogen.
Structure determination and analysis
X-ray diffraction data were processed using XDS (63), and structures
determined by molecular replacement using Phaser (64), followed by auto-
mated model building using Phenix (65). Models were built using Coot (66)
and refined with REFMAC (67), Phenix (65), and Buster (68). Structures of
cABC, cABCE117C, and cHSP27 have been deposited in the PDB with accession
codes 4M5S, 4M5T, 4MJH respectively.
Buried surface areas in the dimer interface were calculated using the
PISA server (69). 3L1G and 2WJ7 were used for calculations for API and APII.
Sequence alignments were generated using the ClustalW2 server (70). Amino
acids were coloured according to their score in the Gonnet Pam250 matrix
generated by the ClustalW2 server (<0:red; =<0.5:orange, >0.5:yellow), and
fully conserved residues were not coloured (Fig. 2A). Surface hydrophobicity
was calculated and rendered using the UCSF Chimera (71).
Mass spectrometry
MS measurements were carried out on a IM QToF (Synapt G1, Waters)
modified to incorporate a linear drift tube (72). Nanoelectrospray mass
spectra were acquired under conditions optimised for the preservation of
noncovalent interactions essentially as described previously (51) and with
the following instrument parameters: sample cone 10 V, extraction cone
5 V, trap 10 V, trap gas (argon): 2.6 ml/min, drift-cell pressure (helium)
2.14 Torr. Unless stated otherwise, samples were analysed at monomeric
concentrations of 10-20 μM in 200 mM ammonium acetate pH 6.9. DTT, to a
final concentration of 5 mM, was added where stated. For subunit exchange
experiments, 13C-labelled and unlabelled protein was mixed at equimolar
ratios at 4 °C and analysed by MS as soon as possible after mixing (<1 min).
CCSs were measured by mixing oxidized cABCE11C and
13C-labelled cABC,
and then recording spectra at nine drift voltages in the range 50-200 V. At
each drift voltage, arrival times were fitted to normal distributions, and the
transport time (T0) of ions from the exit of the drift-tube region to the time-






































































arrival time (Ta) distributions of the 7+ charge state at each drift voltage
VD using where z is the charge of the
ion, T is the temperature in K, P the pressure in Torr, and the constant
amalgamates the length of the drift tube with the necessary components
of the Mason-Schamp equation (49, 72). The data from all drift voltages
were combined and fitted globally to a normal distribution. Theoretical CCSs
of API-APIII were calculated from the cABC crystal structure using CCSCalc
(Waters) with a gas radius of 1 Å and tolerance of 0.1%, and normalized to
the experimentally determined CCS value of APII for comparison.
NMR spectroscopy
NMR experiments were performed on a 600 MHz spectrometer (Varian)
equipped with a 5 mm z-axis gradient triple-resonance probe. 15N-labelled
cABC and cABCE117C were prepared in 25 mM sodium phosphate, 2 mM
EDTA, 2 mM sodium azide, pH 7.5 and concentrated to 500 μM using amicon
concentrators (Millipore, UK). 2D 15N-1H HSQC correlation spectra were
recorded with 8 scans per transient with acquisition times (t1, t1) of (65.8,
135.1) ms, over (608, 100) complex points and a 1 s relaxation delay, for a
total acquisition time of 26 min. All spectra were analysed using NMRPipe
(73) and Sparky (T. D. Goddard and D. G. Kneller, University of California,
San Francisco). Peaks were ascribed to particular residues based on the
previous assignment of a similar construct (74). To measure chemical shift
perturbations (CSPs) in both dimensions, the chemical shift difference in the
nitrogen dimension was divided by 5 to account for the distribution of shifts
recorded in the BMRB. In the few cases where several peaks could not be
clearly assigned in the cABCE117C spectrum, the furthest peak was used for
CSP calculations in order not to under-estimate the CSP. If the closest peak
was used instead, the pattern of CSPs was very similar, although the CSPs
were slightly smaller (Fig. S2C, D).
In vitro protein aggregation assays
The aggregation and precipitation of the target proteins, reported
via either ThT fluorescence or light-scattering assays, was monitored by
using sealed 96-microwell plates and Fluostar Optima plate reader (BMG
Labtechnologies). The amorphous aggregation of α-lac (Sigma-Aldrich, 100
μM), incubated at 37 °C in 50 mM phosphate buffer containing 100 mM
NaCl and 5 mM EDTA, pH 7.0, was initiated by the addition of DTT (20
mM). Chaperones were added at the molar ratios stated. Aggregation was
monitored by measuring the change in apparent absorbance due to light
scattering at 340 nm, which was negligible in the absence of α-lac. The
formation of amyloid fibrils by target proteins was monitored using an in
situ ThT-binding assay (75). κ-casein (Sigma-Aldrich, 50 μM) was incubated at
37 °C in 50 mM phosphate buffer (pH 7.4), and Aβ1-42 (Anaspec, 10 μM) at 37
°C in PBS (pH 7.4). Chaperones and DTT (20 mM) were added where stated at
a molar ratio of 1:2 (chaperone:κ-casein) or 1:20 (chaperone:Aβ1-42). Samples
were incubated with 10 μM ThT and the fluorescence levels measured with
a 440/490 nm excitation/emission filter set. The change in ThT fluorescence
in the absence of either κ-casein or Aβ1-42 was negligible for each assay. In
all cases, the relative ability of each chaperone to prevent aggregation was
evaluated by comparing the apparent absorbance/ThT fluorescence at the
end of each assay, as previously described (76). Data are reported as mean
± SEM (n = 3) and were analysed by one-way ANOVA and Tukey’s post-hoc
test. To assay exposed hydrophobicity, samples were prepared at 2.5 μM in
PBS and bis-ANS was added to a final concentration of 10 μM. Fluorescence
spectra were recorded as previously described (60).
Cell viability assays
Cell viability was measured by using a CellTiter 96 aqueous non-
radioactive cell proliferation assay kit (Promega #G4100). PC-12 (ATCC cat.
# CRL-1721), HeLa and HEK293 cell lines were used to assess the inhibition of
our ABC constructs on Aβ1-42 toxicity. HeLa and HEK293 cells were cultured
in DMEM medium with 10% fetal bovine serum. PC12 cells were cultured
in ATCC-formulated RPMI 1640 medium (ATCC) with 10% heat-inactivated
horse serum and 5% fetal bovine serum. All cells were maintained at 5% CO2
at 37 °C. For cell viability measurements, HeLa, HEK293 and PC-12 cells were
plated out in 96-well plates (Costar) at 10000 cells/well, and cultured for 20 h
at 37 °C in 5% CO2 before adding different incubation mixtures. These were
prepared to a final concentration of 5 μM Aβ1-42 monomer in PBS (pH 7.4),
in the presence or absence of chaperone as indicated, and incubated at 37
°C for 18 h. 10 μL of incubated sample was added to each well containing 90
μL cell suspension. After 24 h incubation, 15 μL “dye” solution was added to
each well, and the cells incubated for a further 4 h before the addition of 100
μL “solution/stop mix” to each well. After incubation at room temperature
for 12 h, the absorbance of each well was measured at 570 nm, with the
background absorbance recorded at 700 nm. The final data were normalized
by using the buffer-treated cell as 100% viability and 0.2% SDS-treated cell
as 0% viability. Data are reported as mean ± SEM (n = 4) and the titration
series were analysed globally using an unpaired Student’s T-test. Specifically,
the plateau of viability at high ratios of chaperone: Aβ1-42 was determined
by fitting the data to an exponential rise to maximum (77), and compared to
the absence of chaperone altogether.
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